Angiotensin AT1 receptor-mediated attenuation of cardiac hypertrophy due to volume overload: involvement of endothelin.
The role of angiotensin II via the angiotensin type 1 (AT1) receptor in the development of volume overload cardiac hypertrophy was investigated in adult male Wistar rats with aortic insufficiency. We examined the effects of specific angiotensin AT1 receptor blockade with losartan (2-n-butyl-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl) biphenyl-4-yl)methyl]-imidazole potassium) on left ventricular weight and left ventricular angiotensin II and endothelin-1 level to test the possibility that the cardiac action of angiotensin II may be mediated by endogenous endothelin-1. Moreover, to verify the possible involvement of endothelin-1, we measured left ventricular endothelin-1 levels during the hypertrophic process and evaluated the effect of the endothelin ETA receptor specific antagonist, FR139317 ((R)2-[(R)2-[(S)-2-[[1-(hexahydro-1H-azepinyl)]carbonly] amino-4-methylpentanoyl]amino-3-[3-(1-methyl-1H-indolyl) propionyl]amino-3-(2-pyridyl) propionic acid), on left ventricular weight. Two weeks after production of aortic insufficiency, left ventricular weight and left ventricular endothelin-1 concentration were markedly elevated in the rats with aortic insufficiency as compared with the sham-operated control rats, but left ventricular angiotensin II was not changed. Losartan (10 mg/kg/day p.o., 2 weeks) significantly reduced left ventricular weight and left ventricular endothelin-1 level in the rats with aortic insufficiency without affecting blood pressure and there was a significant positive correlation between left ventricular weight and left ventricular endothelin-1 content. Left ventricular endothelin-1 content correlatively increased to left ventricular weight during the development of the left ventricular hypertrophy.(ABSTRACT TRUNCATED AT 250 WORDS)
D000595:Amino Acid Sequence; D000804:Angiotensin II / Q000378:metabolism; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001381:Azepines / Q000494:pharmacology; D001713:Biphenyl Compounds / Q000494:pharmacology; D002306:Cardiac Volume / Q000502:physiology*; D006332:Cardiomegaly / Q000188:drug therapy / Q000209:etiology*; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000378:metabolism / Q000502:physiology*; D006321:Heart / Q000187:drug effects; D006352:Heart Ventricles / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy / Q000209:etiology; D007093:Imidazoles / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D019808:Losartan; D008297:Male; D008969:Molecular Sequence Data; D009206:Myocardium / Q000378:metabolism / Q000648:ultrastructure; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D011945:Receptors, Angiotensin / Q000145:classification / Q000502:physiology*; D013777:Tetrazoles / Q000494:pharmacology; D013997:Time Factors
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001381:Azepines; D001713:Biphenyl Compounds; D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D007093:Imidazoles; D007211:Indoles; D011945:Receptors, Angiotensin; D013777:Tetrazoles; D000804:Angiotensin II; C079574:FR 139317; D019808:Losartan